Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun
Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice
from the National Medical Products Administration approving a domestically
manufactured drug‑registration clinical trial application for injectable
GenSci136. GenSci136 is Jinsai’s self‑developed BAFF/APRIL dual‑target
antagonist, classified in China as a Class 1 therapeutic biological product and
intended for treatment of Sjögren’s syndrome.
